The E7 oncoprotein of the high risk human papillomavirus type 16 (HPV-16), which is etiologically associated with uterine cervical cancer, is a potent immortalizing and transforming agent. It probably exerts its oncogenic functions by interacting and altering the normal activity of cell cycle control proteins such as p21 WAF1 , p27 KIP1 and pRb, transcriptional activators such as TBP and AP-1, and metabolic regulators such as M2-pyruvate kinase (M2-PK). Here we show that E7 is a short-lived protein and its degradation both in vitro and in vivo is mediated by the ubiquitin-proteasome pathway. Interestingly, ubiquitin does not attach to any of the two internal Lysine residues of E7. Substitution of these residues with Arg does not aect the ability of the protein to be conjugated and degraded; in contrast, addition of a Myc tag to the N-terminal but not to the C-terminal residue, stabilizes the protein. Also, deletion of the ®rst 11 amino acid residues stabilizes the protein in cells. Taken together, these ®ndings strongly suggest that, like MyoD and the Epstein Barr Virus (EBV) transforming Latent Membrane Protein 1 (LMP1), the ®rst ubiquitin moiety is attached linearly to the free N-terminal residue of E7. Additional ubiquitin moieties are then attached to an internal Lys residue of the previously conjugated molecule. The involvement of E7 in many diverse and apparently unrelated processes requires tight regulation of its function and cellular level, which is controlled in this case by ubiquitin-mediated proteolysis. Oncogene (2000) 19, 5944 ± 5950.
Introduction
The E7 oncoprotein of the high risk human papillomavirus type 16, which is etiologically associated with pathogenesis of human uterine cervical cancer, is a potent immortalizing and transforming protein. Expression of E7 can transform rodent ®broblasts (Kanda et al., 1988) , and in conjunction with an activated Ras oncogene, primary rodent cells (Phelps et al., 1988) . Continued expression of the E7 gene is required for the maintenance of the transformed phenotype (Crook et al., 1989) , and expression of the protein in nonmetastatic mouse cell lines renders the cells metastatic in nude mice (Chen et al., 1993) . In transgenic mice, co-expression of E7 along with E6, another high risk HPV oncoprotein, elicits epidermal hyperplasia (Auewarakul et al., 1994) , verrucose lesions and papillomas (Greenhalgh et al., 1994) . Furthermore, E6 and E7 can cooperate to induce various tumors when expressed ectopically in transgenic mice (Arbeit et al., 1993; Pan and Griep, 1994) . Finally, both E7 and E6 are necessary and sucient to immortalize their primary host cells, human squamous epithelial cells (HawleyNelson et al., 1989; Munger et al., 1989) .
While the molecular mechanisms that underlie the transforming and immortalizing activity of E7 are still obscure, the protein appears to exert most of its oncogenic functions by interacting physically with key cellular regulatory proteins which leads to modulation of their normal activity. One main function of E7 is its ability to deregulate control of cell cycle progression, allowing cells to exit G0 and enter S phase. It has been shown that via its cd2 domain, E7 binds to the cell cycle regulators p107, p130 and pRb (Arroyo et al., 1993; Davies et al., 1993; Hu et al., 1995) . Normally, these proteins function as transcriptional repressors that lead to G1 arrest. It was suggested that the binding of E7 to these proteins leads to their dissociation from their complex with E2F which correlates with stimulation of E2F-dependent transcription. It has also been shown that E7 interacts with both p27 KIP1 (Zerfass-Thome et al., 1996) and p21 WAF1 (Funk et al., 1997) . Consequently, both proteins fail to block the activity of Cyclin E/Cdk2 complexes which allow transition of the cell across the G1/S border. Binding of E7 to the Jun component of AP-1 can lead to activation of AP-1 driven genes (Antinore et al., 1996) . It has been also shown that E7 binds to M2-pyruvate kinase (M2-PK), lowers its anity to phosphoenol-pyruvate, and thus slows in¯ux of substrates into the tricarboxylic, citric acid cycle (Zweschke et al., 1999) . This leads to accumulation of upstream phosphometabolites which serve as precursors to amino acids and nucleotides. The pool of these precursors is low in resting cells, but its expansion is necessary during rapid cell division. E7 can act however in a dierent mechanism; similar to targeting of p53 for degradation by HPV E6 (Schener et al., 1990) , it has been shown that association of E7 with pRb also targets the repressor for ubiquitinmediated degradation (Boyer et al., 1996) . Targeting of pRb, and potentially of other regulatory proteins, for degradation, may serve as a second mechanism, besides physical interaction, by which E7 exerts its deregulatory eects. In the case of pRb, removal of the protein induces the activity of the E2F family of cellular transcription factors which are known to control the expression of the major cell cycle regulatory genes at the G1/S transition. It has been reported that E7 is short-lived (Selvey et al., 1994) , however the system involved in its degradation and the mechanism(s) that underlie the process have remained obscure. Many studies have implicated the ubiquitin pathway in the degradation of various short-lived key regulatory proteins. It is involved in proteolysis and processing of many cellular proteins, including cell cycle regulators, oncoproteins and tumor suppressors, transcriptional activators, ER membrane proteins and cell surface receptors. In most cases, ubiquitination of the target protein signals its degradation by the 26S proteasome. Degradation of a protein via the ubiquitin-proteasome pathway involves two discrete and successive steps: (i) covalent attachment of multiple ubiquitin molecules to the protein substrate; and (ii) degradation of the tagged protein by the 26S proteasome. Conjugation of ubiquitin involves activation and transfer of ubiquitin from the ubiquitinactivating enzyme, E1, to one of several ubiquitincarrier proteins, E2s (known also as ubiquitin-conjugating enzymes, UBCs). E2 transfers the activated ubiquitin moiety to the target substrate that is speci®cally bound to a member of the ubiquitin-protein ligase family, E3. Subsequent processive transfer of additional activated ubiquitin molecules and their conjugation to previously attached moieties, generates a polyubiquitin chain that serves as a degradation signal for the proteasome. Binding of the substrate to E3 plays an essential role in speci®c substrate recognition (for recent reviews on the ubiquitinproteasome pathway, see, for example, Kornitzer and Ciechanover, 2000; Voges et al., 1999) . In most cases, the ®rst ubiquitin molecule is transferred to an e-NH 2 group of an internal Lysine residue of the target protein. However, targeting of the myogenic transcription factor MyoD (Breitschopf et al., 1998) and of the Epstein Barr Virus (EBV) Latent Membrane Protein-1 (LMP-1; Aviel et al., 2000) involves initial ubiquitination of the N-terminal residue followed by synthesis of a poly-ubiquitin chain attached to an internal Lys residue of this N-terminally attached ubiquitin moiety. Thus, unlike many known substrates of the ubiquitin system, degradation of these proteins does not require any internal Lys residue. It has also been reported that a mutant lysine-less a chain of the T cell receptor (TCR) is also degraded by the proteasome, in a process that depends on an intact ubiquitin system. However, a role for direct ubiquitination of the substrate, as well as identi®cation of potential ubiquitination sites, has not been discerned (Yu and Kopito, 1999) . Similarly, ubiquitin-mediated endocytosis and degradation of the growth hormone receptor also proceeds in the absence of any lysine residue (Govers et al., 1999) . The inability to identify ubiquitin adducts of the two receptors lead to the hypothesis that ubiquitination of another, yet to be identi®ed factor, plays a role in the endocytic process.
Discovery of additional substrates is essential in order to establish N-terminal ubiquitination as a novel targeting pathway, to analyze the structural motifs involved, to identify the conjugating enzymes, and in particular the ubiquitin ligase, E3, and to study the physiological signi®cance of this new pathway.
Here we show that HPV-16 E7 is a novel substrate of the ubiquitin pathway that is targeted for degradation via N-terminal ubiquitination.
Results
Degradation of E7 in a cell free reconstituted system requires ATP, formation of a polyubiquitin chain and the ubiquitin-carrier protein E2-F1
To study the mechanisms that underlie the degradation of E7, we reconstituted a cell free proteolytic system. As can be seen in Figure 1a , degradation of the protein requires three components, ATP, ubiquitin, and the ubiquitin carrier protein (E2) E2-F1 (E2-F1 is the rabbit homolog of the human UbcH7). Omission of any one of these components from the reaction mixture, abolished degradation. To further study the mechanism of ubiquitin action, we investigated whether formation of a polyubiquitin chain is required to promote degradation. To that end, we used the methylated derivative of ubiquitin that can modify the target protein only once and serves as a chain terminator (Hershko and Heller, 1985) . As can be seen in Figure 1b , MeUb strongly inhibited degradation of E7 in the cell free system. This inhibition can be alleviated by the addition of excess free WT ubiquitin. To demonstrate directly generation of a substrate anchored polyubiquitin chain, we incubated labeled E7 in crude HeLa cell extract in the absence or presence of ATPgS. This nucleotide can support the activity of the ubiquitin activating enzyme E1 (in which the a-b bond is utilized), but not the activity of the 26S proteasome that requires cleavage of the b-g bond (Johnston and Cohen, 1991). As can be seen in the experiment depicted in Figure 1c , incubation of labeled E7 in the presence of ATPgS generates a polyubiquitin chain that is anchored to the substrate.
Degradation of E7 in cells is mediated by the proteasome
To study the mechanism(s) that underlie degradation of E7 in vivo, we followed the stability of the protein in cells in the absence or presence of the speci®c proteasome inhibitor lactacystin. As can be seen in Figure 2 , E7 is a short lived protein. Measurements in dierent experiments have demonstrated that the half life of the protein is *30 ± 40 min (see also Figure 7 ). Here, after 1 h, more than 70% of the protein is degraded. Addition of lactacystin inhibited degradation completely.
Degradation of a lysine-less E7 in a cell free reconstituted system requires ATP, formation of a polyubiquitin chain and the ubiquitin-carrier protein E2-F1
We have previously shown that degradation of the transcriptional activator MyoD requires attachment of the ®rst ubiquitin moiety to the N-terminal free amino acid residue and not to any internal Lys residue of the protein (Breitschopf et al., 1998) . Similarly, ubiquitinmediated degradation of the Latent Membrane Protein 1 (LMP1) of the Epstein-Barr Virus is not dependent on the single internal Lys residue of the molecule, and also requires initial fusion of ubiquitin to the Nterminal residue (Aviel et al., 2000) . To study whether a similar mechanism is also involved in the degradation of E7, we replaced the two Lys residues in positions 60 and 97 with Arg. As can be seen in the experiment depicted in Figure 3 , similar to the WT protein, degradation of the lysine-less E7 in a cell free reconstituted system also requires ubiquitin, E2-F1, and ATP ( Figure 3a ). Degradation requires formation of a polyubiquitin chain (Figure 3b ,c). As noted for MyoD and LMP1, the amount of ubiquitin adducts formed is lower in the case of the lysine-less mutant (compare c in Figures 1 and 3) , suggesting that in the WT protein, internal Lys residues can also play a role, though not an essential one, in the proteolytic process.
Degradation of lysine-less E7 in cells depends on an active proteasome
Similar to the WT protein, degradation of the lysineless mutant in cells is also mediated by the proteasome (Figure 4) .
Blocking of the N-but not of the C-terminus of E7 inhibits both conjugation and degradation of E7 both in vitro and in vivo
To study the involvement of the N-terminal domain in targeting the protein for N-terminal residue ubiquitination, we fused a 66Myc tag to the N-terminal and the Cterminal residues of E7. We predicted that if the Nterminal domain is involved in speci®c recognition of the protein, and ubiquitin will be fused only to a certain amino acid sequence, moving of this sequence downstream from the N-terminal domain will inhibit both conjugation and degradation. Indeed, as can be seen in Figure 5 , conjugation of an N-terminally Myc-tagged WT E7 (that contains the two internal Lys residues) is strongly inhibited compared to a similar protein that contains a Myc tag fused to its C-terminal residue (Figure 5a ). Similarly, while the degradation of a Cterminally Myc-tagged E7 in a cell free system proceeds eciently, the degradation of an N-terminal Myc-tagged WT protein is strongly inhibited (Figure 5b ). Not surprisingly, the degradation of a similar Lysine-less mutant is also inhibited (Figure 5b ). We noted that the C-terminally tagged mutant migrates slower than its Nterminally tagged counterparts; the reason for this peculiar behavior is not known. Similarly, in cells, Nterminally tagged WT and lysine-less E7s are stable, unlike the C-terminally tagged WT protein ( Figure 6 ).
The N-terminal domain of E7 contains the ubiquitination signal
To study directly the role of the N-terminal domain of E7 as a ubiquitination signal, we deleted the ®rst 11 or 7 amino acids of the protein. As can be seen in Figure  7a , deletion of the ®rst 11 residues stabilizes the S-methionine labeled E7 was monitored in a cell free reconstituted system that contained reticulocyte Fraction II as described under Materials and methods. Ubiquitin, ATP, and E2-F1 were added as indicated. To avoid contamination of the labeled substrate with E2-F1, it was fractionated over DEAE prior to its addition to the reaction mixture as described under Materials and methods. (b) Degradation of E7 requires ubiquitin and formation of a polyubiquitin chain. Degradation of in vitro translated and labeled E7 was monitored in a cell free reconstituted system that contained HeLa cell Fraction II and ATP as described under Materials and methods. Ubiquitin, and MeUb were added as indicated. (c) Conjugation of ubiquitin to E7. In vitro translated and labeled E7 was incubated in complete HeLa cell extract in the absence or presence of ATPgS as indicated and as described under Materials and methods Figure 2 Degradation of E7 in cells is sensitive to proteasome inhibition. Cos 7 cells were transiently transfected with cDNA coding for E7. Degradation of the protein was monitored in a pulse-chase labeling and immunoprecipitation experiment in the absence or presence of the cell permeable proteasome inhibitor clasto-lactacystin b-lactone as described under Materials and methods
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In contrast, degradation of a mutant protein from which the ®rst 7 amino acid residues were deleted, proceeded similarly to that of the WT protein ( Figure  7b ). The ®nding that the signal is constituted of a relatively long segment raises the hypothesis that it serves not only as an anchor for speci®c ubiquitination, but also as a binding site for the ubiquitin ligase E3.
Discussion
Ubiquitin-mediated degradation of multiple key regulatory proteins is involved in the regulation of many basic cellular processes. Here we show that the HPV E7 oncoprotein is a substrate for the ubiquitin system. It is degraded in an ATP-dependent manner in a process that requires also ubiquitin and the ubiquitin-carrier protein E2-F1/UbcH7 (Figure 1a) . It is not clear whether this E2 is the only carrier protein involved, or whether other E2s, such as members of the UbcH5 family that are involved in the degradation of the bulk Figure 4 Degradation of lysine-less E7 in cells is sensitive to proteasome inhibition. Cos 7 cells were transiently transfected with cDNA coding for lysine-less E7. Degradation of the protein was monitored in a pulse-chase labeling and immunoprecipitation experiment in the absence or presence of the cell permeable proteasome inhibitor clasto-lactacystin b-lactone as described under Materials and methods S-methionine labeled lysine-less E7 was monitored in a cell free reconstituted system that contained reticulocyte Fraction II as described under Materials and methods. Ubiquitin, ATP, and E2-F1 were added as indicated. To avoid contamination of the labeled substrate with E2-F1, it was fractionated over DEAE prior to its addition to the reaction mixture as described under Materials and methods. (b) Degradation of lysine-less E7 requires ubiquitin and formation of a polyubiquitin chain. Degradation of in vitro translated and labeled lysine-less E7 was monitored in a cell free reconstituted system that contained HeLa cell Fraction II and ATP as described under Materials and methods. Ubiquitin, and MeUb were added as indicated. (c) Conjugation of ubiquitin to lysine-less E7. In vitro translated and labeled lysine-less E7 was incubated in complete HeLa cell extract in the absence or presence of ATPgS as indicated and as described under Materials and methods S-methionine-labeled WT-E7 were subjected to ATPgS-driven conjugation in a complete HeLa cell extract that contains also ubiquitin. Reactions were carried out and conjugates resolved via SDS ± PAGE as described under Materials and methods. (b) Degradation of N-and C-terminally Myc-tagged WT, and N-terminally Myc-tagged lysine-less E7 in a cell free system. WT [WT(N)] and lysine-less [LL (N)] Nterminally Myc-tagged and WT [WT (C)] C-terminally Myctagged E7 were subjected to degradation in a cell free system containing complete HeLa cell extract, ubiquitin, and ATP. Reactions were carried out and proteins resolved via SDS ± PAGE as described under Materials and methods of cellular proteins, are also required. The identity of the ubiquitin-protein ligase E3 that binds the substrate speci®cally is still obscure. Degradation of E7 requires formation of a polyubiquitin chain: the chain terminator methylated ubiquitin inhibits degradation of E7, and inhibition can be relieved by the addition of excess free WT ubiquitin (Figure 1b ). Indeed, we were able to demonstrate directly formation of polyubiquitinated E7 following incubation of the protein in the presence of ATPgS (Figure 1c ). This nucleotide promotes formation of conjugates, but inhibits their degradation. In cells, E7 is extremely unstable and has a t 1/2 of * 30 ± 40 min. Incubation of cells in the presence of lactacystin, a speci®c proteasome inhibitor, inhibited degradation almost completely (Figure 2) .
To further dissect the mechanisms that underlie the recognition and degradation of E7, it was important to study whether a speci®c Lys residue is essential for formation of the polyubiquitin chain, or whether the two Lys residues in positions 60 and 97 can equally serve as anchors to the polyubiquitin chain. We individually replaced each of the two Lys residues with Arg, however, we could not observe any eect on either ubiquitin-mediated conjugation and degradation in vitro, or on the stability of the protein in vivo (not shown). Therefore, we decided to replace these two residues. However, when incubated in a cell free reconstituted system, and similar to the behavior of the WT protein, degradation of the lysine-less E7 was still dependent on ATP, E2-F1, and ubiquitin ( Figure  3) . Also, in cells, degradation of the lysine-less protein was sensitive to inhibition of the proteasome ( Figure  4) . As no lysine residues were available for ubiquitination, we suspected that the ®rst ubiquitin residue is attached to the free N-terminal NH 2 group, as is the case for MyoD (Breitschopf et al., 1998) and EBV LMP1 (Aviel et al., 2000) . To study the possibility that E7 is also targeted via initial N-terminal ubiquitination, and with the assumption that the N-terminal domain of the protein determines the speci®city for this process, we altered the N terminal domain of both WT and the lysine-less E7 by fusing it with a Myc-tag. For both forms, tagging resulted in major stabilization of the protein in vitro (Figure 5b ) and in vivo ( Figure  6 ). Concomitantly, we noted a marked decrease in conjugation of the tagged WT protein in a cell free system (Figure 5a ). This decrease occurred despite the presence of the two internal Lys residues in the protein. The eects of Myc tagging on both conjugation and degradation are even more striking if one takes into consideration the existence of additional six lysine residues in the tag. The ®nding that the Myctagged WT E7 can still be conjugated is probably due to the existence of the two internal lysine residue. Interestingly, while after 60 min the protein appears stable (Figure 6 ), it is still degraded in a much slower rate in a ubiquitin dependent mode (not shown). This ®nding demonstrates that the internal lysine residues (either of the protein and/or of the tag) can play a role in the process, though not a major one. In the native protein, they may serve as modulators of proteolysis. A similar observation was noted also for MyoD and Figure 7 Degradation of 11 (a) and 7 (b) amino acid residues Nterminally deleted E7s in cells. (a) Degradation of 11 amino acid residues N-terminally deleted WT E7. Cos 7 cells were transiently transfected with a cDNA that codes for E7 lacking the ®rst 11 amino acid residues (residues 2 ± 12; DN11). Stability of the WT and the deletion mutant were monitored in a pulse-chase labeling and immunoprecipitation experiment as described under Materials and methods. Band intensities were quanti®ed by analysis of the imaging data and plotted as relative percentage of the signal at time 0. (b) Degradation of 7 amino acid residues N-terminally deleted WT E7. Cos 7 cells were transiently transfected with a cDNA that codes for E7 lacking the ®rst 7 amino acid residues (residues 2 ± 8; DN7). Stability of the WT and the deletion mutant and quantitative analysis of the data were carried out as described under Materials and methods and above LMP1. The Myc tag can aect the stability of a protein that is targeted for degradation following ubiquitination of the N-terminal residue by blocking the access of ubiquitin, the ligase, or both, to a speci®c ubiquitination site and/or recognition motif at the Nterminal domain. To test this notion directly, we deleted the ®rst 7 and 11 N-terminal amino acid residues. As can be seen in Figure 7 , deletion of the ®rst 11 residues stabilized the protein signi®cantly. In contrast, deletion of the ®rst seven residues was not sucient to confer stability. Our initial results indicate that deletion of amino acid residues 8 ± 11 results in stabilization of the protein, suggesting that they may play an important role in the recognition and targeting of the protein (unpublished data). Obviously, it will be important to study whether this sequence can serve as a`universal' transferrable N-terminal destabilizing element. It should be noted, however, that we could not ®nd sequence homology between the N-terminal regions of E7, MyoD, LMP1, and TCRa (it is not clear that this protein is degraded via N-terminal ubiquitination; Yu and Kopito 1999), but such functional motifs or epitopes may be generated following folding of the protein rather than at the primary sequence level. It is quite possible that the motifs are dierent and targeted by dierent ligases. Future identi®cation of the E3 will be necessary to resolve the question of whether the N-terminal region serves also as a recognition site for the ligase. In this context it is worth mentioning the case of the Cdk inhibitor p21
Cip1
, where the researchers suggested that, similar to ODC, the protein is targeted by the proteasome in a process that does not involve ubiquitination (Shea et al., 2000) ; a lysine-less Nterminally Myc-tagged protein is still unstable and degraded in a proteasome-dependent manner.
It should be emphasized that N-terminal ubiquitination is dierent from the recognition via the N-end rule (Varshavsky, 1996) where the protein is recognized via the N-terminal residue, but conjugation occurs on internal lysines.
It is clear that for N-terminal ubiquitination to occur, a protein must have a free and exposed Nterminal residue. Thus, proteins acetylated at the Nterminal residue cannot be targeted via this pathway. While 80% of cellular proteins are modi®ed at the Nterminal residue by acetylation (JoÈ rnvall, 1975) , 20% bear free and exposed N-termini. It is possible that these proteins are targeted via N-terminal ubiquitination. Indeed, in agreement with the set of`rules' that determines, according to the three N-terminal residues, whether a protein will be acetylated, E7 that has MHG as its ®rst three residues, should not be modi®ed. However, since the set of`rules' was determined for an extremely limited number of proteins, mostly yeast proteins (Polevoda et al., 1999; Boissel et al., 1988; Huang et al., 1987) , it is not clear whether it is possible to predict which proteins will be subjected to N-terminal ubiquitination. The hypothesis however can be tested experimentally. Furthermore, manipulation of proteins by altering their N-terminal domain and rendering them susceptible or resistant to acetylation, can also corroborate or rule out the notion that N-terminal ubiquitination is the pathway of`choice' for free and exposed N-termini proteins. Plasmids and construction of mutant cDNAs WT and lysineless mutant E7 cDNAs were subcloned into the EcoRI ± XbaI site of the pCS2 and pCS2+MT vectors (Breitschopf et al., 1998; Aviel et al., 2000) . These vectors were used for both in vitro translation (under the control of SP6 RNA polymerase) and expression in mammalian cells. Point mutations in E7 were generated by site-directed mutagenesis using the QuickChange TM kit (Stratagene). Deletion of the ®rst 7 (DN7) or 11 (DN11) N-terminal amino acid residues of E7 was carried out using PCR and speci®c primers. PCR products were digested with EcoRI and XbaI and ligated into the pCS2 vector. In-frame insertion of 66Myc tag in the N or C termini of E7 was carried out using the pCS+MT vector and the appropriate PCR primers. Sequences of all constructs were con®rmed using an automatic sequencing system (ABI 310).
Materials and methods

Materials
Preparation and fractionation of crude reticulocyte lysate Reticulocytes were induced in rabbits and lysates were prepared as described (Hershko et al., 1983) . The lysate was fractionated over DEAE cellulose onto unadsorbed material (Fraction 1) and high salt eluate (Fraction II) as described (Hershko et al., 1983) . E2-F1 was prepared from Fraction I as described (Blumenfeld et al., 1994) . HeLa cell extract was prepared by hypotonic lysis as described previously (Orian et al., 2000) and fractionated as described above.
Conjugation and degradation of E7 in a cell free reconstituted system The E7 cDNAs were translated in the presence of [ 35 S]Methionine using wheat germ coupled transcriptiontranslation extract (TNT 1 , Promega) and SP6 RNA polymerase. When indicated, the crude lysate that contains the labeled substrate was fractionated over DEAE resin to Fraction I and II as described above. The labeled substrate was contained in Fraction II. Conjugation and degradation assays in a cell-free systems were performed as described elsewhere (Breitschopf et al., 1998; Aviel et al., 2000) . Brie¯y, reaction mixture contained in a ®nal volume of 12.5 ml : 50 mg whole HeLa cell lysate proteins, or 50 mg reticulocyte Fraction II and 1 mg E2-F1 as indicated, 5 mg ubiquitin, and *25 000 CPM of in vitro translated labeled E7. Reactions were performed in the presence of 0.5 mM ATP and an ATP-regenerating system (10 mM phosphocreatine and 5 mg phosphocreatine kinase), or ATPgS (5 mM) as indicated. For depletion of ATP, 0.5 mg hexokinase and 20 mM deoxyglucose were added. When indicated, the chain terminator methylated ubiquitin (MeUb; Hershko and Heller, 1985) was added at 5.0 mg. In these reactions ubiquitin was present at 1.0 mg. To overcome the inhibition of MeUb, 15 mg of ubiquitin were added. Conjugation assays contained in addition 0.5 mg of the isopeptidase inhibitor ubiquitin aldehyde (UbAl; Hershko and Rose 1987) . Degradation reactions were carried out at 378C for 2 h, whereas conjugation assays were incubated at 378C for 1 h. Reactions were terminated by the addition of sample buer and resolved by SDS ± PAGE (15%). E7 was visualized by PhosphorImager (Fuji, Japan) Stability of proteins in vivo Cellular stability of E7 proteins was monitored in a pulse-chase labeling and immunoprecipitation experiments as described (Breitschopf et al., 1998) . The proteasome inhibitor clasto-lactacystin b-lactone (10 mM) was added 20 min prior to the end of the labeling period (pulse) and was present throughout the experiment. Following labeling, cells were harvested (time 0: pulse) or were further incubated for the indicated periods of time (chase).
Cells were lysed, and the labeled proteins were precipitated using anti-E7 antibody. Immune complexes were collected using immobilized protein G. Following SDS ± PAGE (15%), proteins were visualized by a PhosphorImager.
Protein concentration Protein concentration was determined according to Bradford (1976) using BSA as a standard.
